Prestige Consumer Healthcare (PBH) Income towards Parent Company (2010 - 2025)
Prestige Consumer Healthcare (PBH) posted quarterly Income towards Parent Company of $46.7 million for Q4 2025, down 23.49% year-over-year from $61.0 million in Q4 2024, and up 10.63% quarter-over-quarter from $42.2 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Income towards Parent Company (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Income towards Parent Company history runs 16 years deep, the most recent figure standing at $46.7 million for Q4 2025.
- In Q4 2025, Income towards Parent Company fell 23.49% year-over-year to $46.7 million; the TTM figure through Dec 2025 stood at $186.5 million (down 12.82% YoY), while the FY2025 annual figure was $214.6 million, up 2.52% from the prior year.
- Income towards Parent Company for Q4 2025 stood at $46.7 million, up from $42.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was $61.0 million in Q4 2024, with the low at -$240.6 million in Q1 2023.
- The 5-year median for Income towards Parent Company is $50.6 million (2021), against an average of $35.9 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company tumbled 561.84% in 2023, then surged 120.56% in 2024.
- Prestige Consumer Healthcare's Income towards Parent Company stood at $50.2 million in 2021, then grew by 3.46% to $52.0 million in 2022, then climbed by 2.11% to $53.0 million in 2023, then climbed by 15.05% to $61.0 million in 2024, then slipped by 23.49% to $46.7 million in 2025.
- Business Quant data shows PBH's Income towards Parent Company at $46.7 million in Q4 2025, $42.2 million in Q3 2025, and $47.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Prestige Consumer Healthcare | 2.42 Bn | 2.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.70 Mn |
| Sep 30, 2025 | 42.21 Mn |
| Jun 30, 2025 | 47.47 Mn |
| Mar 31, 2025 | 50.13 Mn |
| Dec 31, 2024 | 61.03 Mn |
| Sep 30, 2024 | 54.38 Mn |
| Jun 30, 2024 | 49.07 Mn |
| Mar 31, 2024 | 49.46 Mn |
| Dec 31, 2023 | 53.05 Mn |
| Sep 30, 2023 | 53.56 Mn |
| Jun 30, 2023 | 53.28 Mn |
| Mar 31, 2023 | -240.55 Mn |
| Dec 31, 2022 | 51.95 Mn |
| Sep 30, 2022 | 51.02 Mn |
| Jun 30, 2022 | 55.27 Mn |
| Mar 31, 2022 | 52.09 Mn |
| Dec 31, 2021 | 50.22 Mn |
| Sep 30, 2021 | 45.33 Mn |
| Jun 30, 2021 | 57.76 Mn |
| Mar 31, 2021 | 35.51 Mn |